Neuropatia periférica em pessoas com mieloma múltiplo
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | http://hdl.handle.net/1843/64367 |
Resumo: | Objective: To investigate the prevalence and incidence of peripheral neuropathy (PN) related to antineoplastic therapy in people with multiple myeloma and the association between chemotherapy regimens and peripheral neuropathy after treatment. Method: This is a documentary and correlational study carried out in two reference sites for cancer treatment, located in the Brazilian states of Ceará and Minas Gerais, with an analysis of patients treated between January 2013 and January 2016. A descriptive and inferential analysis of data was carried out by means of chi-square and Fischer’s exact tests. Results: The study assessed 100 medical records of people with multiple myeloma, who were aged 62.7 years on average and were mostly men (64%). The most used chemotherapy regimen (60%) was bortezomib, dexamethasone, and cyclophosphamide; 20% of patients had peripheral neuropathy before treatment, 68% had it during treatment and 56% at the end of treatment. There was no association between chemotherapy regimens and peripheral neuropathy after treatment.Conclusion: Our study showed an increase in the incidence of PN in individuals undergoing treatment of multiple myeloma, 80% had symptoms of neuropathy before and/or during and/or after treatment with chemotherapy regimens. Predominance was of elderly retired men. The most common chemotherapy regimen was bortezomib/dexamethasone/cyclophosphamide and there was no association between regimens used and PN after treatment. The implications of these observations rest on the need for a permanent assessment of PN in people with multiple myeloma, in addition to a strict follow-up to this event in the course of treatment and after it, as well as the management of adverse events and alterations related to the disease. There was no association between chemotherapy regimens and peripheral neuropathy after treatment. It is expected that the results obtained help in the organization of a data record about PN in patients with cancer, with the main purpose of establishing targets of intervention, thus making care more effi cient and comprehensive. |
id |
UFMG_f9b6c77982c8e66802d37ea2e175810c |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/64367 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
Neuropatia periférica em pessoas com mieloma múltiploPeripheral neuropathy in people with multiple myelomaSíndromes neurotóxicasAntineoplásicosMieloma múltiploManifestações neurológicasQuimioterapia combinadaAntineoplásicosSíndromes NeurotóxicasMieloma múltiploObjective: To investigate the prevalence and incidence of peripheral neuropathy (PN) related to antineoplastic therapy in people with multiple myeloma and the association between chemotherapy regimens and peripheral neuropathy after treatment. Method: This is a documentary and correlational study carried out in two reference sites for cancer treatment, located in the Brazilian states of Ceará and Minas Gerais, with an analysis of patients treated between January 2013 and January 2016. A descriptive and inferential analysis of data was carried out by means of chi-square and Fischer’s exact tests. Results: The study assessed 100 medical records of people with multiple myeloma, who were aged 62.7 years on average and were mostly men (64%). The most used chemotherapy regimen (60%) was bortezomib, dexamethasone, and cyclophosphamide; 20% of patients had peripheral neuropathy before treatment, 68% had it during treatment and 56% at the end of treatment. There was no association between chemotherapy regimens and peripheral neuropathy after treatment.Conclusion: Our study showed an increase in the incidence of PN in individuals undergoing treatment of multiple myeloma, 80% had symptoms of neuropathy before and/or during and/or after treatment with chemotherapy regimens. Predominance was of elderly retired men. The most common chemotherapy regimen was bortezomib/dexamethasone/cyclophosphamide and there was no association between regimens used and PN after treatment. The implications of these observations rest on the need for a permanent assessment of PN in people with multiple myeloma, in addition to a strict follow-up to this event in the course of treatment and after it, as well as the management of adverse events and alterations related to the disease. There was no association between chemotherapy regimens and peripheral neuropathy after treatment. It is expected that the results obtained help in the organization of a data record about PN in patients with cancer, with the main purpose of establishing targets of intervention, thus making care more effi cient and comprehensive.Objetivo: Investigar a prevalência e incidência de neuropatia periférica relacionada ao tratamento com antineoplásicos de pessoas com mieloma múltiplo bem como a associação entre os esquemas quimioterápicos e a neuropatia periférica após o tratamento. Método: Estudo documental, correlacional, realizado em dois locais de referência para tratamento oncológico, localizados nos estados do Ceará e Minas Gerais, com análise de pacientes atendidos entre janeiro/2013 e janeiro/2016. Os dados foram analisados utilizando-se análise descritiva e inferencial a partir dos testes qui-quadrado e exato de fisher. Resultados: Foram avaliados 100 prontuários de pessoas com mieloma múltiplo com média de idade de 62,7 anos, maioria de homens (64%). O esquema quimioterápico mais utilizado (60%) foi o bortezomibe, dexametasona e ciclofosfamida; 20% dos pacientes apresentavam neuropatia periférica antes do tratamento, 68% desenvolveram durante o tratamento e 56% ao finalizar o tratamento. Não houve associação entre os esquemas quimioterápicos e a neuropatia periférica após o tratamento.Conclusão: O presente estudo mostrou um aumento da incidência de NP em indivíduos em tratamento para o MM, 80% apresentaram sintomas de neuropatia antes e/ou durante e/ou após o tratamento com esquemas quimioterápicos. A predominância foi de homens idosos aposentados. O esquema quimioterápico mais utilizado foi o VDC e não foi identificada associação entre os esquemas utilizados e a NP após término o tratamento. As implicações dessas observações recaem sobre a necessidade de avaliação contínua da NP em pessoas com MM, além da monitorização rigorosa desse evento no decorrer do tratamento e após o mesmo, bem como o manejo dos eventos adversos e alterações relacionadas a doença. Não houve associação entre os esquemas quimioterápicos e a neuropatia periférica após o tratamento. Espera-se que os resultados obtidos auxiliem na organização de um registro de dados sobre NP em pacientes com câncer, com o objetivo principal de determinar alvos de intervenção, tornando o cuidado mais eficiente e integral.Universidade Federal de Minas GeraisBrasilENF - DEPARTAMENTO DE ENFERMAGEM BÁSICAUFMG2024-02-20T18:49:04Z2024-02-20T18:49:04Z2018info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlepdfapplication/pdf10.1590/1982-019420180006119820194http://hdl.handle.net/1843/64367porActa Paulista de EnfermagemMaysa Mayran Chaves MoreiraAndrea Bezerra RodriguesPatrícia Peres OliveiraMaria Isis Freire de AguiarGilmara Holanda da CunhaRoberta Marjorie Cunha PintoDeborah Francielle FonsecaLuciana Regina Ferreira Pereira da Matainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2024-02-20T19:43:09Zoai:repositorio.ufmg.br:1843/64367Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2024-02-20T19:43:09Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.none.fl_str_mv |
Neuropatia periférica em pessoas com mieloma múltiplo Peripheral neuropathy in people with multiple myeloma |
title |
Neuropatia periférica em pessoas com mieloma múltiplo |
spellingShingle |
Neuropatia periférica em pessoas com mieloma múltiplo Maysa Mayran Chaves Moreira Síndromes neurotóxicas Antineoplásicos Mieloma múltiplo Manifestações neurológicas Quimioterapia combinada Antineoplásicos Síndromes Neurotóxicas Mieloma múltiplo |
title_short |
Neuropatia periférica em pessoas com mieloma múltiplo |
title_full |
Neuropatia periférica em pessoas com mieloma múltiplo |
title_fullStr |
Neuropatia periférica em pessoas com mieloma múltiplo |
title_full_unstemmed |
Neuropatia periférica em pessoas com mieloma múltiplo |
title_sort |
Neuropatia periférica em pessoas com mieloma múltiplo |
author |
Maysa Mayran Chaves Moreira |
author_facet |
Maysa Mayran Chaves Moreira Andrea Bezerra Rodrigues Patrícia Peres Oliveira Maria Isis Freire de Aguiar Gilmara Holanda da Cunha Roberta Marjorie Cunha Pinto Deborah Francielle Fonseca Luciana Regina Ferreira Pereira da Mata |
author_role |
author |
author2 |
Andrea Bezerra Rodrigues Patrícia Peres Oliveira Maria Isis Freire de Aguiar Gilmara Holanda da Cunha Roberta Marjorie Cunha Pinto Deborah Francielle Fonseca Luciana Regina Ferreira Pereira da Mata |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Maysa Mayran Chaves Moreira Andrea Bezerra Rodrigues Patrícia Peres Oliveira Maria Isis Freire de Aguiar Gilmara Holanda da Cunha Roberta Marjorie Cunha Pinto Deborah Francielle Fonseca Luciana Regina Ferreira Pereira da Mata |
dc.subject.por.fl_str_mv |
Síndromes neurotóxicas Antineoplásicos Mieloma múltiplo Manifestações neurológicas Quimioterapia combinada Antineoplásicos Síndromes Neurotóxicas Mieloma múltiplo |
topic |
Síndromes neurotóxicas Antineoplásicos Mieloma múltiplo Manifestações neurológicas Quimioterapia combinada Antineoplásicos Síndromes Neurotóxicas Mieloma múltiplo |
description |
Objective: To investigate the prevalence and incidence of peripheral neuropathy (PN) related to antineoplastic therapy in people with multiple myeloma and the association between chemotherapy regimens and peripheral neuropathy after treatment. Method: This is a documentary and correlational study carried out in two reference sites for cancer treatment, located in the Brazilian states of Ceará and Minas Gerais, with an analysis of patients treated between January 2013 and January 2016. A descriptive and inferential analysis of data was carried out by means of chi-square and Fischer’s exact tests. Results: The study assessed 100 medical records of people with multiple myeloma, who were aged 62.7 years on average and were mostly men (64%). The most used chemotherapy regimen (60%) was bortezomib, dexamethasone, and cyclophosphamide; 20% of patients had peripheral neuropathy before treatment, 68% had it during treatment and 56% at the end of treatment. There was no association between chemotherapy regimens and peripheral neuropathy after treatment.Conclusion: Our study showed an increase in the incidence of PN in individuals undergoing treatment of multiple myeloma, 80% had symptoms of neuropathy before and/or during and/or after treatment with chemotherapy regimens. Predominance was of elderly retired men. The most common chemotherapy regimen was bortezomib/dexamethasone/cyclophosphamide and there was no association between regimens used and PN after treatment. The implications of these observations rest on the need for a permanent assessment of PN in people with multiple myeloma, in addition to a strict follow-up to this event in the course of treatment and after it, as well as the management of adverse events and alterations related to the disease. There was no association between chemotherapy regimens and peripheral neuropathy after treatment. It is expected that the results obtained help in the organization of a data record about PN in patients with cancer, with the main purpose of establishing targets of intervention, thus making care more effi cient and comprehensive. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018 2024-02-20T18:49:04Z 2024-02-20T18:49:04Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
10.1590/1982-0194201800061 19820194 http://hdl.handle.net/1843/64367 |
identifier_str_mv |
10.1590/1982-0194201800061 19820194 |
url |
http://hdl.handle.net/1843/64367 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Acta Paulista de Enfermagem |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
pdf application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil ENF - DEPARTAMENTO DE ENFERMAGEM BÁSICA UFMG |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil ENF - DEPARTAMENTO DE ENFERMAGEM BÁSICA UFMG |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
repositorio@ufmg.br |
_version_ |
1816829848841093120 |